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Perivascular innate immune events modulate early
murine vein graft adaptations
Binh T. Nguyen, MD, Peng Yu, MD, Ming Tao, MD, Shuai Hao, BS, Tianyu Jiang, BS, and
C. Keith Ozaki, MD, Boston, Mass
Objective: Innate immunity drives numerous cardiovascular pathologies. Vein bypass grafting procedures are frequently
accompanied by low-grade wound contamination. We hypothesized that a peri-graft innate immune challenge, via an
outside-in route, augments inflammatory responses, which subsequently drive a component of negative vein graft wall
adaptations; moreover, adipose tissue mediates this immune response.
Methods: The inferior vena cava from a donor mouse was implanted into the common carotid artery of a recipient mouse
utilizing a validated cuff technique (9-week-old male C57BL/6J mice). Slow-release low-dose (5 g) lipopolysaccharide
(LPS) (n  9) or vehicle (n  9) was applied peri-graft; morphologic analysis was completed (day 28). In parallel,
vein-graftedmice received peri-graft LPS (n 12), distant subcutaneous LPS (n 6), or vehicle (n 12), then day-1 and
-3 harvest of grafts and adipose tissue for cytokines and toll-like receptor (TLR) signalingmRNA expression (qRT-PCR).
Results: All recipient mice survived, and all vein grafts were patent. Acute low-dose local LPS challenge enhanced vein
graft lumen loss (P  .04) and tended to augment intimal hyperplasia (P  .06). The surgical trauma of vein grafting
universally upregulated key pro- and anti-inflammatory mediators within the day-1 graft wall, but varied on TLR
signaling gene expression. Local and distant LPS accentuated these patterns until at least postoperative day 3. LPS
challenge enhanced the inflammatory response in adipose tissue (locally > distantly); local LPS upregulated adipose
TLR-4 dramatically.
Conclusions: Perivascular and distant inflammatory challenges potentiate the magnitude and duration of inflammatory
responses in the early vein graft wall, negatively modulating wall adaptations, and thus, potentially contribute to vein
graft failure. Furthermore, surgery activates innate immunity in adipose tissue, which is augmented (regionally >
systemically) by LPS. Modulation of these local and distant inflammatory signaling networks stands as a potential
strategy to enhance the durability of vascular interventions such as vein grafts. ( J Vasc Surg 2013;57:486-92.)
Clinical Relevance: Vein graft failure is traditionally considered as a process driven by luminal hemodynamic forces and
endothelial injury. We report that the “outside-in” mechanism of local perivascular and distant inflammatory challenges
potentiate the magnitude and duration of inflammatory responses in the early vein graft wall, negatively modulating wall
adaptations, and thus potentially contribute to vein graft failure. Modulation of these inflammatory signaling networks
(eg, extension of antibiotic administration beyond standard wound prophylaxis regimens) stands as a potential strategy
to enhance the durability of vascular interventions such as vein grafts.
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iClinical vein graft durability remains limited, and fail-
ure mechanisms have historically been attributed to factors
such as hemodynamic forces and inflammation acting
largely via the luminal surface. The innate immune system
evolved to protect the host from invading pathogens, and it
participates in the tissue response to injury.1 Its activation
in the context of vascular injury has been increasingly
associated with cardiovascular pathologies.2 For instance,
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486nflammatory biomarkers of high-sensitivity C-reactive pro-
ein, fibrinogen, and serum amyloid A are correlated with
he severity of peripheral arterial diseases, and elevated
-reactive protein is associated with increased risk for post-
perative vascular events.3 Innate inflammation has been
lso linked to the pathogenesis and progression of athero-
clerosis and thrombosis.4 Toll-like receptors (TLRs) play
ey roles in innate mediated events, and are associated with
ntimal hyperplasia in the setting of arterial injury5 and
etabolic disorders such as obesity and type 2 diabetes
ellitus.6-8 Recent evidence specifically suggests that
LR-4 also regulates the adaptive response of vein grafts to
rterialization.9
Various host contexts activate innate immunity. Infec-
ion, whether chronically in the form of periodontal disease
r acutely in the setting of surgical site infection, can prime
he host immune response.10 A vein bypass grafting proce-
ure usually takes many hour to perform, and low-grade
acterial contamination likely occurs (as high as 79%11) in
ost cases. Wound complications/infections have been
dentified as independent predictors of accelerated vein
raft failure.12 Furthermore, vein conduits often lie adja-
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Volume 57, Number 2 Nguyen et al 487cent to soft tissues such as adipose tissue, which is capable of
orchestrating local inflammatory responses.13-16 These ex-
ample host settings may upregulate vascular inflammation,
but direct evidence linking a hyperactive immune response
(originating from a perivascular stimulus such as local
wound contamination) to vein graft failure remains sparse.
We, thus, hypothesized that a local immune challenge
initiated in the perivascular space can lead to an exaggerated
inflammatory response that elicits vein graft wall events via
an “outside-in” paradigm to drive subsequent negative
adaptations. In addition, adipose tissue, being an anatom-
ically dominant component of the peri-graft space, can
potentially function as a mediator of this host innate im-
mune response.
METHODS
The mouse vein graft model. Nine-week-old male
C57BL/6J mice were purchased from the Jackson Labora-
tory (Bar Harbor, Me). Animals were maintained on a
12-hour light-dark cycle, and received water and standard
chow ad libitum. All animal experiments were performed
according to protocols approved by the Institutional Ani-
mal Care andUse Committee and complied with theGuide
for the Care and Use of Laboratory Animals (National In-
stitutes of Health Publication No. 85-23, Revised 1996).
Operative procedures were performed aseptically, with
general continuous inhalant anesthesia (1%-2% isoflurane
mixed with 1 L/min oxygen), using a Zeiss binocular
OPMI-MD Surgical Microscope (Carl Zeiss Inc, Oberko-
chen, Germany).
A mouse vein bypass isograft model was created via
interposition of a supradiaphragmatic inferior vena cava
(IVC) from a donor mouse into the common carotid artery
of a recipient mouse as previously reported.17,18 Briefly, the
mouse right common carotid artery was dissected and
ligated with 9-0 nylon sutures at the midpoint and divided.
After clamping, the ligatures were removed and the proxi-
mal and distal artery ends were everted over premade
polyetheretherketone cuffs (Zeus Inc, Orangeburg, SC).
The IVC was then sleeved over the cuffed arterial ends and
secured into position with 9-0 sutures.
Morphologic impact of low-dose perivascular lipo-
polysaccharide (LPS) challenge on mouse vein grafts.
Experimental groups are shown in Table I. Biologically
inert pluronic F-127 gel (# P2443; Sigma Aldrich, St.
Louis, Mo) served as a sustained release vehicle19,20 to
deliver LPS (lipopolysaccharide suspended in pluronic
F-127 gel [gLPS]; from E coli; # L4391; Sigma Aldrich;
n 9) or control normal saline (gNS; n 9) onmouse vein
grafts. Briefly, pluronic gel powder was sterilized via auto-
clave, then reconstituted (40% w/v) in filtered 0.9% saline.
Low-dose LPS was then combined with the gel to create a
suspension that was placed via syringe (5 g LPS/40 L,
per application) topically on the mid- and distal-graft im-
mediately after vein bypass construction. The proximal vein
graft is obscured by the sternocleidomastoid muscle.
Blood was collected via the retro-orbital technique at
days 1 and 7 postoperatively, and plasma was used for systemic cytokine analysis (including tumor necrosis
actor-alpha [TNF-], interleukin [IL]-1, IL-1, IL-2,
L-4, IL-5, IL-6, IL-12 p40 and p70, IL-13, and
L-17) by custom-made Luminex multiplex cytokine-
etection bead assay platform using a Luminex 200 instru-
ent (Luminex Corp, Austin, Tex).
At postoperative day 28, vein grafts were harvested via
hole-body perfusion fixation (10% formalin) under phys-
ological mean arterial pressure (100 mm Hg). After stan-
ard tissue processing, paraffin embedding, and sectioning
6 m), cross-sections for Masson’s trichrome staining
ere obtained 600 m and 800 m (one from each loca-
ion) from the landmark (distal cuff edge) to avoid artifact
rom the anastomotic cuffs and to assay the area exposed to
he gel.
Digital microscopic images were captured using an
xio A1 microscope (Carl Zeiss). Lumen boundary, inter-
al elastic lamina, and outside boundary of the Masson’s
tained vein graft cross sections were determined as de-
cribed before17,18 (Fig 1, A and B), and planimetry was
ompleted by a blinded researcher using AxioVision Rel 4.7
oftware (Carl Zeiss). The morphologic calculation meth-
ds were previously described.18
Leukocyte immunohistochemical staining was com-
leted using rat anti-mouse CD45 (1:50; # 550539; BD
harmingen, San Diego, Calif) as the primary antibody,
iotin conjugated anti-rat IgG2b (1:100; # 550327; BD
harmingen) as the secondary antibody, and with antigen
etrieval technique (citrate buffer, pH 6.0). Positive cells
ere counted per defined area of the vein graft wall.
Early vein graft inflammation/adipose signaling
vents. Separate experiments were performed to investi-
ate early vein graft wall inflammatory changes, as well as to
etermine the impact of local vs distant innate immune
hallenges with LPS. Carotid interposition isografts were
erformed in C57BL/6J mice as described above. gLPS
as applied at peri-graft space or injected into distant
flank) subcutaneous adipose tissue with the same dose as
able I. Experimental groups and numbers of (recipient)
ice
roups Day 0 Day 1 Day 3 Day 28
1) gLPS VG 9
2) gNS VG 9
3) Normal mice for
harvesting IVC and
flank SC adipose 6
4) gNS VG
 gNS flank SC adipose 6 6
5) gNS VG
 gLPS flank SC adipose 6
6) gLPS VG
 gNS flank SC adipose 6 6
LPS, Lipopolysaccharide suspended in pluronic F-127 gel; gNS, normal
aline suspended in pluronic F-127 gel; IVC, inferior vena cava; SC, subcu-
aneous; VG, vein graft.tated above; control animals received gNS vehicle. Vein
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February 2013488 Nguyen et algrafts and adipose tissue at the distant injection site were
harvested at days 1 and 3 postoperatively and snap-frozen
in liquid nitrogen. IVC and flank subcutaneous adipose
tissue from normal mice were also collected as baseline
samples (Table I).
Total RNA was isolated from vein grafts and adipose
tissue using RNeasy Mini Kit (QIAGEN Inc, Valencia,
Calif) according to manufacturer’s protocol. Temporal ex-
pression patterns of key pro- and anti-inflammatory medi-
ators (CCL2, TNF-, IL-1, IL-6, IL-10, and TNFAIP3)
as well as components of the TLR pathway (TLR-4,
TLR-2, CD14, Myd88, IKBKB, and MAP3K1) were de-
termined by qRT-PCR using Mouse Toll-Like Recep-
tor Signaling Pathway PCR Array (# PAMM-018;
SABiosciences, QIAGEN Inc) per manufacturer’s in-
structions (interrogated genes shown in Table II). Rela-
tive mRNA expression levels were indexed using Hprt1
Fig 1. Morphologic analysis of day 28 mouse vein grafts
Normal saline suspended in pluronic F-127 gel (gNS) ve
gel (gLPS) vein graft. Scale bar  200 m. C, The
mediaadventitia thickness, the perimeter of internal ela
Masson’s stained images. Values are shown as mean  st(Hypoxanthine guanine phosphoribosyl transferase) and gsp90ab1 (Heat shock protein 90 alpha cytosolic class B)
s housekeeping genes and the 2[C(T)] method.
Statistical analysis. Data are shown as mean  stan-
ard error of the mean. Comparison of more than two
able II. Interrogated mediators
CL2 Chemokine (C-C motif) ligand 2 (MCP-1)
NF Tumor necrosis factor alpha
L-1 Interleukin-1 beta
L-6 Interleukin-6
L-10 Interleukin-10
NFAIP3 Tumor necrosis factor, alpha-induced protein 3
LR-4 Toll-like receptor-4
LR-2 Toll-like receptor-2
D14 CD14 molecule
yd88 Myeloid differentiation primary response gene 88
KBKB Inhibitor of kappa B kinase beta
AP3K1 Mitogen-activated protein kinase kinase kinase 1
, Representative Masson’s trichrome stained images. A,
aft. B, Lipopolysaccharide suspended in pluronic F-127
parison of vein graft lumen area, intimal thickness,
mina, and the perimeter of outside boundary, based on
rd error of the mean.. A-B
in gr
com
stic laroups was performed via one-way analysis of variance;
o
v
T
o
t
d
T
o
s
t
M
C
D
a
a
c
e
a
e
c
l
v
i
l
i
c
t
t
p
s
t
b
t
m
s
c
t
w
w
t
p
g
d
k
r
m
t
b
a
t
c
i
p
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 2 Nguyen et al 489comparison of two groups was performed via unpaired
two-tailed Student’s t-test. Statistical tests were completed
with SigmaPlot v 11.0 (SYSTAT Software Inc, San Jose,
Calif) or Excel 2003 (Microsoft Corp, Redmond, Wash). A
P value of 	.05 was considered statistically significant.
RESULTS
All recipient mice survived until harvest, and all vein
grafts were patent. One gNS vein graft specimen was mi-
croscopically uninterpretable and excluded from subse-
quent analysis.
Acute local LPS challenge enhances negative wall
remodeling and intimal hyperplasia in day-28 vein
grafts. Acute local innate immune challenge during the
early stages of vein grafting led to significant vein graft
lumen area loss (0.56  0.03 mm2 gLPS vs 0.68  0.04
mm2 gNS; P  .04), with trends toward exaggeration of
intimal thickness (53.5  5.6 m gLPS vs 39.2  4.4 m
gNS; P  .06) and inward remodeling (internal elastic
lamina length) (2.94 0.06 mm gLPS vs 3.11 0.09 mm
gNS; P  .12) in peri-graft-gLPS mice (Fig 1). No signif-
icant difference between two groups in leukocyte localiza-
tion was observed on CD45 stained cross sections (Sup-
plementary Fig, online only). Systemic plasma levels of
inflammatory mediators demonstrated no significant differ-
ence between LPS and saline treatment at postoperative
days 1 and 7 (Supplementary Table, online only), suggest-
ing largely paracrine instead of endocrine effects.
Local and distant LPS challenges induce an exag-
gerated inflammation response of early vein graft wall.
Surgical trauma of vein bypass grafting universally up-
regulated key pro- and anti-inflammatory mediators
(CCL2, TNF-, IL-1, IL-6, IL-10, and TNFAIP3)
within the vein graft wall at the immediate postoperative
time (day 1). However, there were subtle differences in the
magnitude of the inflammatory response between the treat-
ment groups: IL-6 cytokine expression appeared signifi-
cantly higher in gLPS-graft animals (2.6-fold higher in-
crease relative to elevated response seen in gNS vein grafts)
(Fig 2, A). At 3 days, inflammation within the vein graft
wall began to subside as inflammatory mediator gene ex-
pression was dampened. gLPS-graft mice, however, exhib-
ited sustained up-regulation of IL-1, IL-10, and
TNFAIP3, as well as higher levels of TNF- (Fig 2, A
and B).
Concurrent with the rise in pro- and anti-inflammatory
cytokine expression within the vein graft wall in this early
time frame is an upregulation of TLR-2, CD14, and
Myd88. TLR-4 and key upstream inflammatory mediators
IKBKB and MAP3K1 were downregulated at both days 1
and 3 (Fig 2, A and B).
Distant subcutaneous LPS challenge (essentially mim-
icking a remote bacterial contamination/infection) also
contributed to the inflammatory changes within the vein
graft wall in a similar pattern. The overall magnitude is
albeit less than local LPS challenge (Fig 2, B).
Adipose tissue contribution to inflammation.
Inflammatory changes also occurred in distant subcutane- kus adipose tissue of animals undergoing surgical trauma of
ein grafting. There were significant increases in CCL2,
NF-, IL-1, and TNFAIP3 expression in the early post-
perative period from baseline. LPS challenge enhanced
his inflammatory response in adipose tissue (locally 

istantly); there were sustained upregulation of CCL2,
NF-, IL-1, IL-6, IL-10, and TNFAIP3 at day 3 post-
peratively. Distinctive from the inflammatory response
een within the vein graft wall, LPS-challenged adipose
issue also exhibited increased TLR-4, IKBKB, and
AP3K1 expression in addition to upregulation of TLR-2,
D14, and Myd88 (Fig 2, C).
ISCUSSION
Vein grafts morphologically adapt to their new arteri-
lized environment through myofibroblast proliferation
nd wall thickening, and innate immunity has been impli-
ated as playing a role in this early adaptive response via
ndogenous signals.9 Ongoing vascular inflammation initi-
ted via tissue traumatic injury from vein grafting and
xacerbated by host biological and hemodynamic factors
an theoretically accelerate intimal hyperplasia, progressive
umen loss and graft failure.21-27 The current study pro-
ides direct evidence that exacerbation of abluminal host
mmunity can enhance inflammation and vein graft lumen
oss. While efforts are made to avoid operation in clinically
nfected patients, the data point out that low-grade wound
ontamination can drive nonvascular wall inflammation
hat can drive revascularization failure. One can speculate
hat antibiotics beyond those utilized for surgical wound
rophylaxis, or anti-inflammatory strategies directed at tis-
ues beyond the vein graft wall (eg, adipose) around the
ime of operation might enhance revascularization dura-
ility.
We selected LPS as a strategic research tool to prime
he host innate immune system and exaggerate the inflam-
atory response associated with surgical trauma in the early
tages of vein graft adaptation. This traditional immune
hallenge enhanced lumen loss and neointimal prolifera-
ion, as seen on the morphologic analyses of the vein graft
alls after 28 days. The lack of difference in CD45 staining
ithin the day-28 vein graft wall of two groups suggests
hat the diverse events elicited may occur at an early time
oints.
Supporting prior reports,23,24,28 longitudinal investi-
ation of this early window of vein graft inflammatory
ynamics revealed an elevation of proinflammatory cyto-
ines in the immediate postoperative period, followed by
esolution of inflammation over time as anti-inflammatory
echanisms are activated. In local gLPS challenged mice,
here was a higher initial surge in IL-6 expression, followed
y more sustained up-regulation of TNF-, IL-1, IL-10,
nd TNFAIP3, suggesting ongoing inflammation within
he vein graft wall. These downstream changes were asso-
iated with TLR-2 andMyd88 stimulation, and concurrent
ncrease in CD14 marker suggesting macrophage partici-
ation. However, TLR-4 was downregulated, along with
ey upstream mediators IKBKB and MAP3K1. While
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February 2013490 Nguyen et alFig 2. mRNA expression of inflammatory mediators. Data are shown as fold induction standard error of the mean. A,
Vein graft (VG)wall at baseline day 0, andpostoperative days 1 and3. §Relative to normal saline suspended in pluronic F-127
gel (gNS) VG at the same time point, P 	 .05. B, VG wall at postoperative day 3. *Relative to normal inferior vena cava
(IVC),P	.05;§Relative to gNSVG (with gNS adipose),P	 .05; †Relative to gNSVG (with lipopolysaccharide suspended
in pluronic F-127 gel [gLPS] adipose), P	 .05.C,Distant (flank) adipose tissue at postoperative day 3. *Relative to normal
adipose, P	 .05; §Relative to gNS adipose (with gNS VG), P	 .05; †Relative to gNS adipose (with gLPS VG), P	 .05.
IL, Interleukin; TNF, tumor necrosis factor-alpha.
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preferential stimulation of TLR-2 over TLR-4 may be
related to the tissue specific response of vein grafts, as well
as the particular variant of LPS used.10,29-33 Downregula-
tion of upstream mediators IKBKB and MAP3K1 kinase in
spite of persistent inflammatory cytokine expression may be
related to suppression from negative feedback mechanisms
at the particular time points sampled. Persistent inflamma-
tory cytokine expression may also be elicited by alternative
inflammatory pathways, or may reflect a complex network
of cellular interactions and contributions from perivascular
environment.
Indeed, the inflammatory dynamics from subcutane-
ous adipose tissue in response to LPS challenge is distinct
from that seen in vein graft. LPS induced pro- and anti-
inflammatory cytokine expression is directly related to up-
regulation of TLR-4, TLR-2, CD14, andMyd88, even at 3
days postoperatively. In addition, simple stress from surgi-
cal trauma elicited adipose tissue inflammation that may
contribute via paracrine and endocrine fashion to the over-
all vascular inflammatory response.
While no significant difference in plasma cytokine levels
between gLPS-graft and saline-graft animals existed during
this early time frame, distant LPS challenge does contribute
to the overall inflammatory response seen in vein graft as
well as adipose tissue. These changes may be related to a
primed systemic cellular response that can intravascularly
home to sites of active injury. The effect from local LPS
induced immunity remains more pronounced than distant
systemic contributions, and this highlights the important
contribution of outside-in mechanisms of vascular inflam-
mation to vein graft failure.
The current study is limited to the use of a known
potent innate immune activator (LPS) to elicit the host
innate immune response. The single, relatively low dose (5
g) of LPS was selected based upon the literature and
preliminary studies indicating that it elicited inflammation
without causing overt local wound complications or acute
illness in the animals. Immune challenge with live microbial
organisms would potentially lead to lack of experimental
reproducibility due to inoculum success variation. Further-
more, the impact of gram-positive bacterial components
such as lipoteichoic acid has not been explored, although
they have been shown to mechanistically activate similar
TLR pathways to initiate inflammation. We built the exper-
iments on short-term RNA dynamics at a time point when
the biological response to vein grafting tends to be
high.23,24 Confirmatory protein quantifications and infor-
mation on the cellular mediators are not offered, and this is
limited by the tissue amounts available in these small vein
graft samples in the early postoperative period. Finally, it is
certainly acknowledged that perivascular immune events
are just one of a host of factors (luminally mediated, hemo-
dynamic, etc) that drive negative vein graft wall remodeling
and intimal hyperplasia. However, these experiments di-
rectly bring to light this previously underappreciated but
clinically relevant factor in this complex orchestra of events.
1In conclusion, we found that a single early perivascular
nflammatory challenge negatively modulates subsequent
ein graft adaptations. Furthermore, surgery also activates
nnate immune pathways in the vein graft wall and adipose
issue that are augmented (regionally 
 systemically) by
PS. Thus, mechanistic studies into vascular adaptations to
cute physical interventions should look beyond the vascu-
ar wall into the surrounding local tissues such as adipose
issue since they can contribute to the overall vascular
daptation. Recognizing the settings of activated host im-
unity and mitigating overexpression especially in the crit-
cal early phases of vein graft adaptation may lead to viable
herapeutic strategies.
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Volume 57, Number 2 Nguyen et al 492.e1Supplementary Fig (online only). CD45 immunohistochemical
analysis of day 28 mouse vein grafts. A, Representative image of
normal saline suspended in pluronic F-127 gel (gNS)-treated vein
graft. B, Representative image of lipopolysaccharide suspended in
pluronic F-127 gel (gLPS)-treated vein graft. The hand-digitally
drawn yellow lines delineate the internal elastic laminas of vein graft
walls.Red arrows show the representative positive cells. Scale bar
50 m. C, Quantitative analysis based on CD45 immunohisto-
chemical images. Values are shown as mean standard error of the
mean. There is no statistical difference between two groups for the
various vascular wall layers.
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February 2013492.e2 Nguyen et alSupplementary Table (online only). Mouse plasma levels of cytokines after vein graft implantation (mean  standard
error of the mean; pg/mL)
Plasma cytokines
Postoperative day 1 Postoperative day 7
gNS-treated gLPS-treated gNS-treated gLPS-treated
TNF 26.02  2.58 31.75  4.19 25.08  5.05 23.45  3.41
IL-1 35.81  11.33 31.75  8.01 94.94  45.09 52.58  11.87
IL-1 48.56  8.19 47.92  10.15 54.21  11.31 53.70  6.52
IL-2 93.85  6.48 90.21  2.59 85.99  3.46 86.52  1.28
IL-4 7.32  0.48 7.02  0.14 7.03  0.24 6.97  0.10
IL-5 3.71  0.39 4.95  0.63 2.95  0.30 3.09  0.37
IL-6 16.18  3.57 13.17  2.47 8.63  2.96 4.57  1.33
IL-12 p40 432.84  61.65 459.93  59.70 643.49  66.03 468.69  48.43
IL-12 p70 9.95  1.83 14.45  5.43 11.55  3.78 8.70  1.23
IL-13 7.89  1.03 6.11  0.80 7.56  1.33 6.71  0.98
IL-17 204.56  46.50 118.43  26.78 98.66  37.35 186.76  32.91gLPS, Lipopolysaccharide suspended in pluronic F-127 gel; gNS, normal saline suspended in pluronic F-127 gel; IL, interleukin; TNF, tumor necrosis factor
alpha.
